We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

By LabMedica International staff writers
Posted on 18 Jul 2024
Print article
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide. Many adults avoid routine blood tests due to their complexity and the long wait times for results, which can lead to delayed interventions or missed diagnoses, resulting in substantial avoidable costs. Now, a groundbreaking diagnostic platform is set to transform the existing global infrastructure by providing lab-accurate, actionable test results that aid in the early detection and prevention of chronic conditions.

Truvian Health (San Diego, CA, USA) has developed an automated benchtop system that allows simple, accurate, and comprehensive routine blood tests to be conducted directly in clinics, doctor’s offices, and pharmacies. Utilizing patented technologies and intelligent integration, Truvian’s compact device offers a convenient and economical alternative to traditional off-site labs, delivering quick, lab-accurate results from just a small blood sample, and enhancing healthcare decision-making. The Truvian system combines clinical chemistry, immunoassay, and hematology tests in one operation and can simultaneously handle multiple types of assays. Its initial offering, a comprehensive wellness panel, covers over 90% of the most commonly requested routine blood tests, requiring only one tube and 8 drops of blood.

Truvian has shared data from various independent clinical studies showing that its system's results match those from central laboratories across an extensive range of tests. The platform has been tested with over 50,000 samples from approximately 5,000 donors to date, achieving a reliability rate of over 98%. This system’s capability to provide central lab-quality results in any setting could fundamentally change the way chronic diseases are detected and managed. Immediate access to results enables healthcare providers to diagnose and treat patients without delay, enhancing patient involvement in their health decisions and improving outcomes. By consolidating blood diagnostics into a single visit, the platform reduces healthcare costs for both patients and systems, simplifies the monitoring and management of chronic conditions, and promotes healthier, longer lives. Truvian is now working towards securing US Food and Drug Administration (FDA) clearance for its blood testing platform.

“We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs,” said Jay Srinivasan, chief executive officer of Truvian.

Related Links:
Truvian Health

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
New
Epstein-Barr Virus Test
ZEUS IFA Epstein-Barr Virus VCA IgG Test
New
Syphilis Infection Test
IMPACT RPR

Print article

Channels

Molecular Diagnostics

view channel
Image: The kit includes a container with a film, a compact optical device for attaching a smartphone, and a diagnostic app (Photo courtesy of KIST)

Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. Late-stage detection often results in major... Read more

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.